香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 以下公告的中文原稿將由國藥控股股份有限公司於 2025 年 8 月 25 日於中國貨幣網網站 (http://www.chinamoney.com.cn)及上海清算所網站(http://www.shclearing.com.cn)發佈，僅供參閲。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 25 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 25 重要提示 发行人承诺将及时、公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 以下公告的中文原稿將由國藥控股股份有限公司於 2025 年 8 月 25 日於上海證券交易所網站 (http://www.sse.com.cn)發佈，僅供參閲。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 25 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 2025年6月30 (除特别注明外,金额单位 | | 2025年6月30日 | 2024年12月31日 | | --- | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 中國，上海 2025 年 8 月 25 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 海外監管公告 国药控股股份有限公司 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 公司债券中期报告 以下公告的中文原稿將由國藥控股股份有限公司於 2025 年 8 月 25 日於上海證券交易所網站 (http://www.sse.com.cn)發佈，僅供參閲。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 （2025 年） 二〇二五年八月 0 国药控股股份有限公司公司债券中期报告（202 ...

Core Insights - The company reported a revenue of 286.04 billion RMB for the first half of 2025, representing a year-on-year decline of 2.95% [1] - Net profit attributable to shareholders was 3.47 billion RMB, down 6.43% year-on-year, with earnings per share at 1.11 RMB [1] Business Segments - The pharmaceutical distribution segment remained stable, accounting for 73.62% of total revenue [1] - The medical device distribution revenue decreased, making up 19.22% of total revenue [1] - The pharmaceutical retail segment achieved growth against the trend, contributing 5.78% to total revenue [1] Cost Management - The company demonstrated effective cost control, with sales, management, and financial expense ratios all declining, optimizing by a total of 0.2 percentage points, which supported profit stability [1]

Core Insights - The company reported a revenue of RMB 286.04 billion for the first half of 2025, representing a year-on-year decrease of 2.95% [1] - Net profit attributable to shareholders was RMB 3.47 billion, down 6.43% year-on-year, with earnings per share at RMB 1.11 [1] - The company is focusing on stable recovery and sustainable business development amidst a rapidly changing policy and market environment [1] Revenue Breakdown - The pharmaceutical distribution segment maintained stable development, with its revenue share decreasing by 0.48 percentage points to 73.62% [1] - The medical device distribution segment saw a slight increase in revenue share by 0.08 percentage points to 19.22%, despite a decline in revenue scale [1] - The pharmaceutical retail segment experienced growth, with its revenue share increasing by 0.36 percentage points to 5.78% [1] Cost Management - The company demonstrated effective cost control during the reporting period, benefiting from reduced financing costs, integrated management measures, and lower business costs [2] - The sales expense ratio, management expense ratio, and financial expense ratio decreased to 2.74%, 1.28%, and 0.35% respectively, collectively optimizing by 0.2 percentage points [2] - These improvements in expense ratios provided strong support for mitigating profit decline [2]

Core Viewpoint - The company reported a decline in revenue and profit for the first half of 2025, indicating challenges in the current market environment while focusing on sustainable business development and compliance management [1] Group 1: Financial Performance - The company achieved revenue of RMB 286.04 billion, a year-on-year decrease of 2.95% [1] - Profit attributable to shareholders was RMB 3.466 billion, down 6.43% year-on-year [1] - Earnings per share stood at RMB 1.11 [1] Group 2: Business Segments - The pharmaceutical distribution segment maintained stable development, with a revenue share decrease of 0.48 percentage points to 73.62% [1] - The medical device distribution segment saw a slight increase in revenue share by 0.08 percentage points to 19.22% despite a decline in revenue scale [1] - The pharmaceutical retail segment experienced growth, with a revenue share increase of 0.36 percentage points to 5.78% [1] Group 3: Cost Management - The company demonstrated effective cost control, benefiting from reduced financing costs and integrated management measures [2] - The sales expense ratio, management expense ratio, and financial expense ratio decreased to 2.74%, 1.28%, and 0.35% respectively, collectively optimizing by 0.2 percentage points [2]

Core Insights - The company reported a revenue of RMB 286.04 billion for the first half of 2025, a decrease of 2.95% compared to the same period last year [1] - Net profit and attributable net profit were RMB 5.34 billion and RMB 3.47 billion, reflecting year-on-year declines of 9.53% and 6.43% respectively [1] Revenue Breakdown - The pharmaceutical distribution segment maintained stable development, with its revenue share decreasing by 0.48 percentage points to 73.62% [1] - The medical device distribution revenue saw a slight decline, with its revenue share increasing by 0.08 percentage points to 19.22% [1] - The pharmaceutical retail segment experienced growth, with its revenue share increasing by 0.36 percentage points to 5.78% [1] Cost Management - The company demonstrated effective cost control, benefiting from reduced financing costs, integrated management measures, and lower business costs [1] - The sales expense ratio, management expense ratio, and financial expense ratio decreased to 2.74%, 1.28%, and 0.35% respectively, with a total optimization of 0.2 percentage points [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SINOPHARM GROUP CO. LTD. * （於中華人民共和國註冊成立之股份有限公司， 在香港以國控股份有限公司之名稱經營業務） （股份代號：01099） 二零二五年中期業績公告 國藥控股股份有限公司（「本公司」、「公司」或「國藥控股」）董事會（「董事會」）欣然宣佈本 公司及其附屬公司（「本集團」）截至二零二五年六月三十日止六個月期間（「報告期間」或 「報告期」）之未經審核中期業績，連同去年同期的比較資料如下： * 本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香 港公司。 - 1 - 中期簡明綜合損益表 截至二零二五年六月三十日止六個月 | | | 截至六月三十日止六個月 | | | --- | --- | --- | --- | | | 附註 | 二零二五年 | 二零二四年 | | | | 人民幣千元 | 人民幣千元 | | | | ...

Group 1 - The core viewpoint of the article highlights the financial performance of China National Pharmaceutical Group Corporation (国药控股) for the six months ending June 30, 2025, indicating a slight decline in revenue and operating profit, while showing a modest increase in comprehensive income attributable to the parent company [1] Group 2 - The company reported operating revenue of 36.363 billion RMB, representing a year-on-year decrease of 1.48% [1] - Operating profit was recorded at 684 million RMB, reflecting a year-on-year decline of 8.28% [1] - Comprehensive income attributable to the parent company was 295 million RMB, which is a year-on-year increase of 1.02% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 1 國藥器械之合併財務報表之主要未經審核財務數據 單位：元 幣種：人民幣 | | | | 本報告期 | | --- | --- | --- | --- | | | 本報告期 | 上年同期 | 比上年同期增減 | | 營業收入 | 36,362,746,042.44 | 36,908,522,536.26 | -1.48% | | 營業利潤 | 684,176,599.68 | 745,979,066.39 | -8.28% | | 歸屬於母公司所有者的 綜合收益總額 | 294,606,310.11 | 291,632,700.32 | 1.02% | | 經營活動產生的現金流 | -2,481,582,321.54 | -7,726,076,201.83 | -67.88% | ...